Skip to main content
. 2022 Apr 6;25(5):104207. doi: 10.1016/j.isci.2022.104207

Figure 6.

Figure 6

Brain sections were analyzed for monoamines and metabolites by HPLC

(A). Two samples from each monkey were analyzed from the caudate, putamen, frontal cortex, hippocampus, and cerebellum of all SIV-infected animals (4 SIV + saline and 4 SIV + deprenyl) and averaged, while a single sample was examined from each substantia nigra. Each brain region was analyzed for the concentrations of dopamine metabolite 3,4-dihydroxyphenylacetic acid (DOPAC, A) and dopamine.

(B). Treatment with deprenyl significantly decreased DOPAC concentrations in the caudate, putamen, and substantia nigra, while SIV, but not deprenyl, significantly increased DOPAC in the frontal cortex [A, 2-way ANOVA, SIV x deprenyl; (caudate; SIV, F (1, 11) = 0.0205, p = 0.889; deprenyl, F (1, 11) = 51.97, ∗∗∗∗p < 0.0001); (putamen; SIV, F (1, 11) = 1.979, p = 0.1871; deprenyl, F (1, 11) = 33.70, ∗∗∗p = 0.0001); (substantia nigra; SIV, F (1, 11) = 0.5178, p = 0.4883; deprenyl, F (1, 11) = 7.859, ∗p = 0.0187); (frontal cortex; SIV, F (1, 11) = 16.05, ∗∗ = 0.0025; deprenyl, F (1, 11) = 06713, p = 0.8008]. Assessment of dopamine concentrations showed that both SIV and deprenyl increased dopamine in the caudate, although there was no interaction. Additionally, SIV, but not deprenyl, significantly increased dopamine in the frontal cortex [B, 2-way ANOVA, SIV x deprenyl; (caudate; SIV, F (1, 10) = 6.711, ∗p = 0.0283; deprenyl, F (1, 10) = 6.711, ∗p = 0.0269); (frontal cortex; SIV, F (1, 10) = 5.360, ∗p = 0.0431; deprenyl, F (1, 10) = 2.168, p = 0.1717)].